One of the Holy Grails in the booming immuno-oncology research field right now involves finding an IL-2 drug that can be used safely and effectively to combat cancer, without the immense toxicity that has largely sidelined the original IL-2 Proleukin. Bristol-Myers Squibb paid Nektar $1.85 billion in upfront cash to partner on NKTR-214 — which has since come under a cloud of uncertainty over flailing response rates in their key demonstration study combining it with Opdivo.
Now a group of scientists at the University of Washington says they built an IL-2 protein therapy all their own, and they’ve launched a new biotech — Neoleukin — to take it forward from mouse studies toward the clinic.
Describing their work to a writer at UW Medicine, the group says they designed their protein to bind specifically to IL-2 beta and gamma receptors to whip up a more potent T cell response to cancer while steering clear of CD25 to circumvent the toxic reaction. By doing that they created a lab model of the drug that the scientists were able to ratchet up the dose on without the lethal reaction.
They also added a complementary component for IL-15 to increase the efficacy and dubbed the drug Neo-2/15, describing it as particularly small and stable. And the game plan is to continue to use their computational skills to improve the drug.
“Neo-2/15 has therapeutic properties that are at least as good as or better than naturally occurring IL-2, but it was computationally designed to be much less toxic,” said Umut Ulge, one of the lead authors of a paper published in Nature.
Neoleukin, though, is hardly the only rival to the throne that Nektar and Bristol-Myers Squibb have been striving for. Laura Shawver’s Synthorx has also been angling for the clinic — in H1 of this year — with their drug candidate Synthorin IL-2, backed by Orbimed and Medicxi. The biotech $THOR went public just a few weeks ago, raising $150 million.
Last November Nektar Therapeutics $NKTR managed to add 1 more patient out of its 38 evaluable stage 4 melanoma patients to the win column with its closely-watched 3-month update on Opdivo/NKTR-214’s objective response rate. That managed to nudge up the ORR from 50% — a figure that routed Nektar’s stock at ASCO — to 53%. But the scientists also pushed up the complete response rate to 24%, maintaining they were satisfied with the improved response they were seeing.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.Free Subscription